Aim: This study aims to explore the accuracy, specificity and laws of axillary lymph node metastasis predicted by sentinel lymph node biopsy (SLNB) by comparing axillary lymph node status via SLNB and axillary lymph node dissection (ALND) with nanocarbon as the tracer. Methods: Forty six patients were retrospectively analyzed. These patients underwent SLNB with nanocarbon as the tracer from March 2013 to April 2014. Results: Two hundred and forty six patients of sentinel lymph node (SLN) were successfully detected. Among these patients, 8 patients had 1 SLN (3.25%), 33 patients had 2 SLN (13.41%), 46 patients had 3 SLN (18.70%), 51 patients had 4 SLN (20.73%), 40 patients had 5 SLN (16.26%), 24 patients had 6 SLN (9.76%) and 24 patients had 7 or more SLN (9.76%). The SLNB success rate of nanocarbon staining in the 246 cases was 99.59%, accuracy rate was 97.06% and sensitivity was 93.22%. Furthermore, false negatives were found in four patients, and the false-negative rate was 6.78%. The number of lymph node metastasis in the SLNB and ALND of early-stage breast cancer was analyzed. When the number of SLN dissection was 1, 2, 3, 4, 5, 6 or 7, the coincidence rate of lymph node metastasis for SLNB and ALND was 80. 00, 84.36, 78.57, 88.89, 90.48, 80.00, 73.68 and 78.36, respectively. Conclusion: Sentinel lymph node biopsy performed using the nanocarbon staining method is simple, easy and reliable, and it can be used to predict the axillary status of breast cancer in the early stage.
Introduction
Axillary lymph node dissection (ALND) is an important part of breast cancer surgery, which has important values for correct staging, prognosis and guiding treatment. However, this also causes many complications, such as upper limb lymphedema, shoulder joint movement disorder, numbness of the adduction side of the upper limb caused by intercostobrachial nerve damage and other symptoms. Data have shown that the metastasis rate of the axillary lymph node of breast cancer in clinical stages I and II was less than 30%. 1 For axillary lymph node-negative patients, ALND cannot improve the overall survival rate and prolong disease-free survival time. Furthermore, it may lead to postoperative complications and affect the function and quality of life. Moreover, it is also an excessive treatment. In recent years, with the application of sentinel lymph node biopsy (SLNB) technology, ALND has been avoided in a considerable proportion of patients in the early stage of breast cancer, which improved the quality of life of patients.
However, methods on improving the accuracy of SLNB and reducing the false-negative rate have been problems that should be studied and solved in clinical settings.
Determining how to improve the detection rate of sentinel lymph node (SLN) and reduce the falsenegative rate has been a focus in clinical settings. Some studies have shown that the effect of radioactive colloid on SLN localization is superior to blue dye, 2, 3 and related studies on super paramagnetic tracer and fluorescent reagent tracer have also been recently reported. 4 The successful rate of SLNB performed by Veronesi 5 and others with a single radionuclide (99mTc) in 163 patients was 98%, and the false-negative rate was 2.5%. The detection rate of SLN, determined by the combination of radionuclide and patent blue, performed by Albertini et al. 6 was 92%, and the coincidence rate was 100%. The research performed by Mariani et al. 7 revealed that the successful rate of SLN with the tracer method was 94-97%, and its accuracy rate could reach 99% when combined with the patent blue method. The above data indicate that the combination method can significantly improve the successful rate and reduce the falsenegative rate of SLNB.
In this study, with nanocarbon as a tracer, SLNB results of the 246 patients with breast cancer in the early stage were retrospectively analyzed to investigate the security and accuracy of nanocarbon as a tracer for SLNB, as well as to investigate the correlation between the metastasis of SLN and axillary lymph nodes.
Methods Objects
Data of 246 breast cancer cases in the early stage were studied, were collected from patients who underwent SLNB in Jiangxi Breast Specialist Hospital from March 2013 to April 2014. All patients were female, and inclusion conditions [1] [2] [3] [4] [5] [6] were as follows: the age of patients ranged between 22 and 81 years, with an average age of 50.9 AE 10.8 years, and the primary tumors were located in the left breast in 140 cases and in the right breast in 106 cases. Types of cases: 27 cases had in situ ductal carcinoma, 16 cases had microinvasive carcinoma, 167 cases had invasive ductal carcinoma, 11 cases had invasive lobular carcinoma, 5 cases had mucinous carcinoma, 9 cases had medullary carcinoma, 6 cases had micropapillary carcinoma, 6 cases had cribriform carcinoma and 1 case had biochemical carcinoma.
Reagent
The carbon nanoparticles suspension injection was used. The main component was nanocarbon materials, and accessory povidone was 0.5 g for each ampoule (approval number: Chinese medicine H 20041829).
Methods
SLNB and operation mode [1] [2] [3] [4] [5] [6] [7] All operators in this study were physicians who have successfully detected SLN for more than 20 cases. The patients were given general anesthesia and were disinfected. After draping, 1 mL of carbon nanoparticles suspension injection was preoperatively injected in three points around the lump and around the halo, with approximately 0.1-0.2 mL for each point. The SLN was frozen for pathological inspection. The breast, tumor tissue, SLN and axillary lymph nodes were paraffin embedded, and the histological standard hematoxylin and eosin staining was performed for tissue biopsy.
Evaluation according to the SLNB criteria
Sentinel lymph node biopsy was performed on 246 patients with breast cancer in the early stage in our hospital. The obtained SLN were detected by frozen pathological examination during the operation, where 191 cases (77.64%) were SLN negative, and 55 cases were SLN positive (22.36%). Furthermore, ALND was performed in 55 patients with positive SLN. In addition, 191 cases of breast cancer were SLN negative. These cases were randomly divided into two groups, including 109 cases without dissection and 81 cases that underwent axillary dissection. These 81 patients were negative in ALND and continuously underwent SLNB and were evaluated according to the SLNB standard established by the University of Louisville in America. 8 
Analysis of SLN metastasis and axillary lymph node metastasis
Sentinel lymph node metastasis and axillary lymph node metastasis were analyzed according to the SLNB data of 246 cases of patients with breast cancer in the early stage, which included the 134 patients (55 cases of positive SLN and 81 cases of negative SLN, randomly grouped) who continuously underwent ALND after SLNB.
Statistics processing
Data were analyzed using SPSS 16.0 software. For different numbers of SLN, the coincidence of SLNB and ALND was tested through the independence of the 2K , 24 cases had 6 SLN (9.76%) and 24 cases had 7 or more SLN (9.76%). SLNB were performed in all 246 patients with breast cancer in the early stage, of which 191 cases (77.64%) were free of SLN metastasis, and 55 cases (22.36%) had SLN metastasis. Lymph nodes with one and two positive metastatic lymph nodes accounted for 59.26% and 22.22% of all metastases, respectively, and there were only 5.55% with more than 5 metastases (Table 1) .
Metastasis results of SLNB-negative patients who underwent ALND
A total of 191 breast cancer patients had negative SLN. These patients were randomly divided into two groups: patients without dissection (n = 109) and patients who underwent axillary dissection (n = 81). ALND were performed in 81 patients with breast cancer in the early stage who were negative in SLNB, among which four metastasis cases were found by pathological detection ( Table 2 ).
The conditions of the four patients with falsepositive SLN are shown in Table 2 . The number of SLN in axillary biopsy was 1, 2, 3 and 4, respectively, and ALNB was performed in patients with five or more SLN, who were negative in SLNB and did not have any positive lymph nodes.Sentinel lymph node biopsy was performed in 246 cases of patients with breast cancer in the early stage, of which SLN was not detected in 1 case, and the detection rate of SLNB was 135 of 136 (99.59%). ALNB was performed in 55 cases of patients with positive SLN. A total of 191 breast cancer patients had negative SLN. These patients were randomly divided into two groups: patients without dissection (n = 109) and patients who underwent axillary dissection (n = 81), and four falsenegative patients were found. Furthermore, 55 cases had true positive SLN metastasis, and 77 cases (81−4) had true negative SLN metastasis. A total of 136 patients had SLNB (81 + 55), and the accuracy rate of SLNB was 97.06% (55 + 81−4/81 + 55). Moreover, four cases were false-negative SLN, 55 cases had positive SLN metastasis, 59(55 + 4) cases had positive axillary lymph node metastasis, and sensitivity was 55/55 + 4 = 93.22%. In addition, false-negative results were found in 4 cases, 59 cases (55 + 4) had positive axillary lymph node metastases, and the falsenegative rate was 6.78% (4/55 + 4) ( Table 3) .
Metastasis results in SLNB-positive patients who underwent ALND
Axillary dissection was performed in patients with breast cancer in the early stage with 1, 2 and 3 positive SLN. Results are shown in Table 4 . The coincidence of the number of SLNB and the number of positive ALNB was statistically analyzed when the numbers of positive SLN was 1, 2 and 3. The 2 × K table was used for the independence test, X 2 = 19.319 a , v = 2, P = 0.000, and the difference was statistically significant. It could be considered that when the numbers of positive SLN were 1, 2 and 3 in the early stage of breast cancer, the coincidence rate of the number of metastases of SLNB and ALND was different. Namely, the coincidence rate was the highest when one SLN was positive, and the coincidence rate was the lowest when the number of positive SLN was three in SLNB.
Analysis of coincidence and in coincidence of the number of metastases of SLNB and ALND in patients with breast cancer in the early stage
The numbers of lymph node metastases of SLNB and ALND in the early stage of breast cancer were analyzed. When the numbers of dissected SLN were 1, 2, Table 5 ). The 2 × K table was used for the independence test in the analysis of the coincidence of SLNB and ALND for the different numbers of lymph nodes, X 2 = 2.626 a , v = 6, P = 0.854, and the difference was not statistically significant. X 2 test was performed for the following groups: the 5-piece lymph node group that had the highest coincidence rate (90.48%) and the group that was a combination of other groups. The results were X 2 = 0.267 a , P = 0.606; and the difference was not statistically significant.
Discussion
In this study, through the analysis of the SLNB results of 246 patients with breast cancer in the early stage, the safety, accuracy, advantages and disadvantages of SLNB with nanocarbon as a tracer, as well as the characteristics of SLNB and the related laws of axillary lymph node metastasis, were investigated.
The necessity of SLNB in the early stage of breast cancer
The data have shown that the axillary lymph node metastasis rate of breast cancer in clinical stages I and II was <30%. 9 For axillary lymph node-negative patients, ALND cannot improve the overall survival rate and prolong disease-free survival time. Furthermore, this may lead to postoperative complications and may affect the function and quality of life of patients and is an excessive treatment. The data of SLNB were analyzed. In Table 1 , we found that, in our hospital, 77.64% (191 cases) of the 246 patients with breast cancer in the early stage were treated with axillary SLNB. Furthermore, no metastases were found in SLNB, and positive SLN were only 22.36%. Furthermore, the metastases existing in one lymph node accounted for 59.26%, the metastases existing in two lymph nodes accounted for the 22.22% (22 cases), and the metastases existing in more than two SLN accounted for only 18.26%. Our data also confirmed that most of the patients in the early stage of breast cancer do not need ALND. SLNB can certainly make most patients with early-stage breast cancer avoid axillary dissection.
Characteristics of nanocarbon as a tracer applied in SLNB of breast cancer
Clinical exploratory research of nanocarbon as a tracer applied in SLNB of breast cancer in the early stage continues to increase. [9] [10] [11] [12] [13] [14] As a tracer, nanocarbon does not enter into the capillaries, does not carry anticancer drugs, has noncancerogenic features and has other such characteristics 12, 15, 16 . In Table 3 , the data of 246 cases of early-stage breast cancer patients, who underwent SLNB with nanocarbon as a tracer from March 2013 to April 2014, were analyzed. SLNB was performed in all 246 cases of patients, in which negative SLN was 77.64%, and positive SLN was only 22.36% ( Table 2 ). The accuracy rate was 97.06%, sensitivity was 93.22%, and results of the axillary dissection performed in 81 patients revealed that four cases had metastasis and the false-negative rate was 6.78%. It can be concluded that a good effect could be achieved when nanocarbon was independently used as a tracer. In this study, 245 cases of SLN were successfully detected in the 246 cases with breast cancer in the early stage. Furthermore, a total of 11 303 pieces of SLN were obtained, with an average piece of 4.59 AE 2.31 in each case, and 3-5 pieces were in obtained in most of the cases. Cases with three pieces accounted for 18.70%, cases with four pieces accounted for 20.73%, and cases with five pieces accounted for 16.26%. Noticeably, compared to the previously used tracers, such as TC 99 and methylene blue, the nanocarbon tracer can demonstrate relatively more lymph nodes, where all 4.59 AE 2.31 SLN can be determined as SLN and where they had clinical values worth discussing. Presently, the number of SLN is not determined to be 1, 2, 3 and 4 pieces, indicating that the anatomic structure of the SLN needs to be studied further. Furthermore, the following phenomena was often found in clinical practice: the stained lymph nodes revealed no metastasis, while the nonstained surrounding lymph nodes revealed metastasis, but this still needs more work to arouse our concern.
Accuracy can be improved by increasing the detection of the number of SLN As the adsorption of nanocarbon can significantly increase the detection of the number of stained lymph nodes, it provides a basis for determining the number of SLN and the reduction of false negatives. From the analysis of the clinical data in Table 5 , we observed that when the number of dissected SLN was 1, 2, 3, 4, 5, 6 and 7 pieces, the coincidence rate of the number of metastatic lymph nodes in SLNB and ALND in patients with breast cancer in the early stage was 80.00, 84.36, 78.57, 88.89, 90.48, 80.00, 73.68 and 78.36, respectively. That is, when the number of SLN was five pieces, the coincidence rate of the check result of SLN and lymph node metastasis after axillary dissection is relatively the highest. The 2 × K table was used for the independence test of the coincidence of the different numbers of SLN in SLNB and ALND (Table 5 ; X 2 = 2.626 a , v = 6, P = 0.854), and the difference was not statistically significant. These results suggest that in the early stage of breast cancer in SLNB, the number of SLN does not affect the coincidence rate in SLNB and ALND, which is obviously inconsistent with current practice. Furthermore, it has been reported in related foreign studies that accuracy could be improved by increasing the detection number of SLN. 17 In the study of SLN carried out at the Breast Center of the University of Luis Weil in the United States, the false-negative rate was 8.3% of SLNB. However, four or more detected SLN could significantly reduce the incidence of false negatives.
The conditions of the four patients with falsepositive SLN are shown in Table 2 . The numbers of SLN in axillary biopsy were 1, 2, 3 and 4 pieces. When the number of SLN was 5 or more, no positive lymph node was found in the axillary lymph node biopsy of SLN, which was negative in the biopsy. Furthermore, no false-negative metastatic lymph nodes were found during biopsy when the number of SLN was five or more. The original data also revealed that no false-negative results were found when the number of SLN was five, and the 9.52% noncompliance rate was caused by unmatched metastasis numbers. Hence, we considered that the more the number of SLN, the smaller the possibility of false negatives. Thus, five lymph nodes can reduce false negatives to relatively the lowest.
In clinical practice, an appropriate tracer can determine a suitable number of lymph nodes. This would prevent the missing out of any SLN and reduce the occurrence of false negatives. However, this needs to be further verified through studies with larger sample sizes.
SLN can be used as an indicator of axillary dissection and an indicator of dissection range
Due to adsorption of the nanocarbon, the detection number of stained lymph nodes significantly increased. An average of 4.59 AE 2.31 pieces of lymph nodes was found in the axillary in each case when nanocarbon was used as a tracer. This was significantly different from conditions where the existing number of SLN was 1 and 2, and on this basis, the analysis of the metastasis status of SLN and axillary lymph nodes revealed certain clinical values. Therefore, ALND in conditions of 1 positive metastasis, 2 positive metastases and 3-6 positive metastases of SLN were analyzed ( Table 4) .
The different numbers of positive SLN in ALND were analyzed, and the 2 × K table was used for the independence test in order to compare the coincidence numbers of SLNB and the positive numbers of ALND, when the positive number was 1, 2 and 3 (X 2 = 19.319 a , v = 2, P = 0.000), and the difference was statistically significant. It could be considered that in the early stage of breast cancer in SLNB, when the number of positive SLN was 1, 2, 3 or more, the coincidence rate of the number of metastatic lymph nodes in axillary dissection was different. That is, when ALND was performed in the condition that the number of positive SLN was one in SLNB, 85.71% of patients had no additional axillary lymph node metastasis, and when ALND was performed in the condition that the number of positive SLN was two in SLNB, 53.85% of patients had additional axillary lymph node metastasis. However, when ALND was performed in the condition that the number of positive SLN was three in SLNB, only 11.11% of patients had no axillary metastasis, and most of the patients had other metastatic lymph nodes. Obviously, this has a very important clinical value; that is, SLN can be used as an indicator of axillary dissection and provide a basis for predicting the axillary dissecting range in breast cancer.
Modification of the surgical incision of SLN when using nanocarbon tracers
For SLNB performed in the early stage of breast cancer, due to the developing temporality of the tracer, the stain color will disappear over time. Therefore, traditional axillary incision, namely, the distance of the three horizontal fingers to the axillary position, was usually adopted. The black lymph vessels and lymph nodes dyed by the nanocarbon revealed an obvious contrast to the background. Nanocarbon is a kind of lymph node tracer with a highly lymphatic system trend. The main raw material for carbon nanoparticles suspension injection is carbon black, which has a particle diameter size of 21 nm. According to the size of the space of the tumor lymphatic capillary wall and the characteristics of the macrophage, the carbon nanoparticles suspension liquid can specifically enter the lymphatic vessels. However, it cannot stain the background, which could be performed using methylene blue or other soluble reagents. The nanocarbon can be strongly adsorbed by lymph nodes. Its stain is persistent, is not limited and affected by time. Therefore, SLNB axillary surgery can be performed at the surgical incision site due to the dyeing characteristics of the nanocarbon; and no additional incision is required. As a result, traditional axillary incision, namely, the three-horizontal-finger distance to the axillary position used in our clinic during breast conserving surgery, was no longer necessary when nanocarbon was used as a tracer in SLNB in the majority of breast cancers. Thus, SLN axillary surgical incision was avoided, and operation time was reduced.
By using the nanocarbon tracer in clinical practice, we were able to find the SLN at the surgical incision, without the need for other additional incisions. We could look for five sentinels as far as possible to reduce the false-negative rate in SLNB. Furthermore, we can determine the range of ALND under the guidance of the number of positive SLN. However, these advantages need to be confirmed in clinical settings. In SLNB of axillary lymph nodes performed in the early stage of breast cancer, the combined application of dye and radionuclide not only improves the detection rate of SLN but also reduces the false-negative rate. Further studies are needed to determine whether nanocarbon, as a SLN tracer, should be mixed with methylene blue or radionuclide, as well as its effects.
